{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:47:14Z","timestamp":1780922834876,"version":"3.54.1"},"reference-count":69,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170628"],"award-info":[{"award-number":["82170628"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32160208"],"award-info":[{"award-number":["32160208"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clinre.2025.102553","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T12:10:31Z","timestamp":1739967031000},"page":"102553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advancements of direct oral anticoagulants in cirrhotic individuals with portal vein thrombosis"],"prefix":"10.1016","volume":"49","author":[{"given":"Zhiqian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiying","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5411-3041","authenticated-orcid":false,"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinre.2025.102553_bib0001","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1111\/liv.14121","article-title":"Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: a prospective study","volume":"39","author":"Noronha Ferreira","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2025.102553_bib0002","doi-asserted-by":"crossref","first-page":"327","DOI":"10.51821\/84.2.327","article-title":"Portal vein thrombosis: an overview of current treatment options","volume":"84","author":"Galante","year":"2021","journal-title":"Acta Gastro-Enterol Belg"},{"key":"10.1016\/j.clinre.2025.102553_bib0003","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s10620-018-5427-3","article-title":"Management of non-tumoral portal vein thrombosis in patients with cirrhosis","volume":"64","author":"Stine","year":"2019","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinre.2025.102553_bib0004","first-page":"73","article-title":"Risk factors associated with portal vein thrombosis in liver cirrhosis: a case-control study","volume":"91","author":"Nadinskaia","year":"2019","journal-title":"Ter Arkh"},{"key":"10.1016\/j.clinre.2025.102553_bib0005","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s12325-020-01550-4","article-title":"Anticoagulation favors thrombus recanalization and survival in patients with liver cirrhosis and portal vein thrombosis: results of a meta-analysis","volume":"38","author":"Wang","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.clinre.2025.102553_bib0006","doi-asserted-by":"crossref","first-page":"682","DOI":"10.4254\/wjh.v14.i4.682","article-title":"Direct oral anticoagulant administration in cirrhotic patients with portal vein thrombosis: what is the evidence?","volume":"14","author":"Biolato","year":"2022","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0007","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.bpg.2017.04.005","article-title":"Reversal of liver fibrosis: from fiction to reality","volume":"31","author":"Zoubek","year":"2017","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102553_bib0008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41575-018-0097-3","article-title":"Hepatic microcirculation and mechanisms of portal hypertension","volume":"16","author":"Gracia-Sancho","year":"2019","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0009","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/liv.13500","article-title":"Decreased portal vein velocity is predictive of the development of portal vein thrombosis: a matched case-control study","volume":"38","author":"Stine","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2025.102553_bib0010","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ajg.2012.452","article-title":"De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes","volume":"108","author":"Maruyama","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102553_bib0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.21037\/atm-20-4912","article-title":"Increased portal vein diameter is predictive of portal vein thrombosis development in patients with liver cirrhosis","volume":"9","author":"Dong","year":"2021","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.clinre.2025.102553_bib0012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/sjg.SJG_100_17","article-title":"The use of nonselective beta blockers is a risk factor for portal vein thrombosis in cirrhotic patients","volume":"24","author":"Zampino","year":"2018","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102553_bib0013","doi-asserted-by":"crossref","DOI":"10.3390\/life10090177","article-title":"Investigation of thrombosis volume, anticoagulants, and recurrence factors in portal vein thrombosis with cirrhosis","volume":"10","author":"Suda","year":"2020","journal-title":"Life"},{"key":"10.1016\/j.clinre.2025.102553_bib0014","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/apt.15137","article-title":"Nonselective beta-blockers and the risk of portal vein thrombosis in patients with cirrhosis: results of a prospective longitudinal study","volume":"49","author":"Nery","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2025.102553_bib0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1007\/s12072-019-09951-6","article-title":"Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis","volume":"13","author":"Xu","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.clinre.2025.102553_bib0016","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1136\/gutjnl-2013-306502","article-title":"Non-selective \u03b2-blockers are associated with improved survival in patients with ascites listed for liver transplantation","volume":"64","author":"Leithead","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.clinre.2025.102553_bib0017","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3350\/cmh.2020.0234","article-title":"\u03b2-blockers in advanced cirrhosis: more friend than enemy","volume":"27","author":"Yoon","year":"2021","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0018","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/liv.13409","article-title":"Non-selective beta-blockers are not associated with increased mortality in cirrhotic patients with ascites","volume":"37","author":"Onali","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2025.102553_bib0019","article-title":"AGA clinical practice update: coagulation in cirrhosis","volume":"157","author":"O'Leary","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2025.102553_bib0020","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.transci.2019.06.008","article-title":"Revisiting the activated protein C-protein S-thrombomodulin ternary pathway: impact of new understanding on its laboratory investigation","volume":"58","author":"Amiral","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.clinre.2025.102553_bib0021","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.jhep.2009.03.013","article-title":"Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development","volume":"51","author":"Zocco","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0022","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/ejh.13688","article-title":"The hemostatic and thrombotic complications of liver disease","volume":"107","author":"McMurry","year":"2021","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clinre.2025.102553_bib0023","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.aohep.2018.12.007","article-title":"The relationship between coagulation disorders and the risk of bleeding in cirrhotic patients","volume":"18","author":"Labidi","year":"2019","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0024","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1097\/MEG.0000000000001982","article-title":"Systemic inflammation as a risk factor for portal vein thrombosis in cirrhosis: a prospective longitudinal study","volume":"33","author":"Nery","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0025","doi-asserted-by":"crossref","first-page":"4773","DOI":"10.3748\/wjg.v28.i33.4773","article-title":"Albumin administration in patients with cirrhosis: current role and novel perspectives","volume":"28","author":"de Mattos","year":"2022","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102553_bib0026","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/hep4.1317","article-title":"Serum albumin is inversely associated with portal vein thrombosis in cirrhosis","volume":"3","author":"Basili","year":"2019","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.clinre.2025.102553_bib0027","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1111\/jth.15797","article-title":"The portal vein in patients with cirrhosis is not an excessively inflammatory or hypercoagulable vascular bed, a prospective cohort study","volume":"20","author":"Driever","year":"2022","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.clinre.2025.102553_bib0028","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.jhep.2021.07.020","article-title":"Predicting portal thrombosis in cirrhosis: a prospective study of clinical, ultrasonographic and hemostatic factors","volume":"75","author":"Turon","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0029","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/hep.32169","article-title":"Nonmalignant portal vein thrombi in patients with cirrhosis consist of intimal fibrosis with or without a fibrin-rich thrombus","volume":"75","author":"Driever","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2025.102553_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100055","article-title":"Fibrin clot properties and thrombus composition in cirrhosis","volume":"7","author":"Driever","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.clinre.2025.102553_bib0031","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41395-018-0421-0","article-title":"Clinical impact and safety of anticoagulants for portal vein thrombosis in cirrhosis","volume":"114","author":"Pettinari","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102553_bib0032","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1055\/s-0040-1713169","article-title":"Endothelial damage of the portal vein is associated with heparin-like effect in advanced stages of cirrhosis","volume":"120","author":"Shalaby","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinre.2025.102553_bib0033","doi-asserted-by":"crossref","first-page":"21852","DOI":"10.1038\/s41598-021-01360-w","article-title":"Human endothelial cells and fibroblasts express and produce the coagulation proteins necessary for thrombin generation","volume":"11","author":"Cohen","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinre.2025.102553_bib0034","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s00464-023-10566-0","article-title":"Portal vein velocity predicts portal vein system thrombosis after splenectomy with esophagogastric devascularization","volume":"38","author":"Wang","year":"2024","journal-title":"Surg Endosc"},{"key":"10.1016\/j.clinre.2025.102553_bib0035","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.4254\/wjh.v7.i27.2774","article-title":"Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis","volume":"7","author":"Stine","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0036","article-title":"The impact of portal vein thrombosis on the prognosis of patients with cirrhosis: a retrospective propensity-score matched study","volume":"8","author":"Chen","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.clinre.2025.102553_bib0037","doi-asserted-by":"crossref","DOI":"10.1111\/j.1478-3231.2012.02785.x","article-title":"Prospective evaluation of anticoagulation and transjugular intrahepatic portosistemic shunt for the management of portal vein thrombosis in cirrhosis","volume":"32","author":"Senzolo","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2025.102553_bib0038","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1136\/gut.2004.042796","article-title":"Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation","volume":"54","author":"Francoz","year":"2005","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.clinre.2025.102553_bib0039","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.cgh.2012.01.012","article-title":"Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis","volume":"10","author":"Delgado","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102553_bib0040","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinre.2025.102553_bib0041","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s00508-018-1351-y","article-title":"Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function","volume":"130","author":"Scheiner","year":"2018","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.clinre.2025.102553_bib0042","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2021.12.022","article-title":"Baveno VII\u2013renewing consensus in portal hypertension","volume":"76","author":"de Franchis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0043","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.jhep.2021.04.029","article-title":"Current knowledge and management of portal vein thrombosis in cirrhosis","volume":"75","author":"Senzolo","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0044","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/hep.31646","article-title":"Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 practice guidance by the American Association for the study of liver diseases","volume":"73","author":"Northup","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.clinre.2025.102553_bib0045","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3904\/kjim.2020.622","article-title":"Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation","volume":"37","author":"Yoo","year":"2022","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.clinre.2025.102553_bib0046","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2019.1604686","article-title":"Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation","volume":"15","author":"Fawzy","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clinre.2025.102553_bib0047","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.jhep.2021.09.003","article-title":"EASL clinical practice guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis","volume":"76","author":"Villa","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0048","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00228-024-03648-y","article-title":"Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data","volume":"80","author":"Diesveld","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinre.2025.102553_bib0049","doi-asserted-by":"crossref","DOI":"10.1177\/10760296221104797","article-title":"The efficacy and safety of anticoagulants in the treatment of cirrhotic portal vein thrombosis: a systematic review and meta-analysis","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Appl Thromb Hemost"},{"key":"10.1016\/j.clinre.2025.102553_bib0050","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s10620-015-4012-2","article-title":"Direct oral anticoagulants in cirrhosis patients pose similar risks of bleeding when compared to traditional anticoagulation","volume":"61","author":"Intagliata","year":"2016","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinre.2025.102553_bib0051","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1177\/10600280211025050","article-title":"Direct oral anticoagulants versus warfarin for treatment of thrombosis or atrial fibrillation in patients with cirrhosis: a retrospective cohort study","volume":"56","author":"Coons","year":"2022","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinre.2025.102553_bib0052","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2020\/9583706","article-title":"Risk factors of portal vein thrombosis after devascularization treatment in patients with liver cirrhosis: a nested case-control study","volume":"2020","author":"Lu","year":"2020","journal-title":"BioMed Res Int"},{"key":"10.1016\/j.clinre.2025.102553_bib0053","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/liv.13285","article-title":"Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis","volume":"37","author":"De Gottardi","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.clinre.2025.102553_bib0054","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/hepr.12895","article-title":"Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis","volume":"48","author":"Nagaoki","year":"2018","journal-title":"Hepatol Res"},{"key":"10.1016\/j.clinre.2025.102553_bib0055","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/MEG.0000000000001958","article-title":"Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis","volume":"33","author":"Ilcewicz","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0056","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/j.cgh.2020.08.007","article-title":"Rates of bleeding and discontinuation of direct oral anticoagulants in patients with decompensated cirrhosis","volume":"19","author":"Mort","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0057","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1186\/s12876-023-02960-8","article-title":"Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102553_bib0058","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.14309\/ajg.0000000000001194","article-title":"Anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis: a prospective observational study","volume":"116","author":"Lv","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinre.2025.102553_bib0059","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/MEG.0000000000001846","article-title":"Efficacy and safety study of direct-acting oral anticoagulants for the treatment of chronic portal vein thrombosis in patients with liver cirrhosis","volume":"32","author":"Ai","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102553_bib0060","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/ejh.12844","article-title":"The efficacy and safety of direct oral anticoagulants vs traditional anticoagulants in cirrhosis","volume":"98","author":"Hum","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clinre.2025.102553_bib0061","doi-asserted-by":"crossref","first-page":"G171","DOI":"10.1152\/ajpgi.00402.2017","article-title":"Role of the blood coagulation cascade in hepatic fibrosis","volume":"315","author":"Pant","year":"2018","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.clinre.2025.102553_bib0062","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/apt.17297","article-title":"Review: the safety of anticoagulants and antiplatelet agents in patients with cirrhosis","volume":"57","author":"Ma","year":"2023","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinre.2025.102553_bib0063","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijsu.2019.02.018","article-title":"Warfarin versus aspirin prevents portal vein thrombosis after laparoscopic splenectomy and azygoportal disconnection: a randomized clinical trial","volume":"64","author":"Bai","year":"2019","journal-title":"Int J Surg"},{"key":"10.1016\/j.clinre.2025.102553_bib0064","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0290164","article-title":"Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: a systematic review and meta-analysis","volume":"18","author":"Liao","year":"2023","journal-title":"PLoS ONE"},{"key":"10.1016\/j.clinre.2025.102553_bib0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.artd.2015.03.004","article-title":"The effect of new oral anticoagulants and extended thromboprophylaxis policy on hip and knee arthroplasty outcomes: observational study","volume":"1","author":"Bottle","year":"2015","journal-title":"Arthroplasty Today"},{"key":"10.1016\/j.clinre.2025.102553_bib0066","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2017-000712","article-title":"Direct oral anticoagulants versus warfarin: is new always better than the old?","volume":"5","author":"Burn","year":"2018","journal-title":"Open Heart"},{"key":"10.1016\/j.clinre.2025.102553_bib0067","first-page":"537","article-title":"Rivaroxaban versus low-molecular weight heparin plus warfarin prevents portal vein system thrombosis after splenectomy and pericardial devascularization: a randomized clinical trial","volume":"20","author":"Yao","year":"2021","journal-title":"EXCLI J"},{"key":"10.1016\/j.clinre.2025.102553_bib0068","article-title":"Comparison of apixaban and aspirin in preventing portal vein thrombosis after laparoscopic splenectomy for cirrhotic hypersplenism","author":"Shi","year":"2024","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinre.2025.102553_bib0069","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1055\/s-0039-1679934","article-title":"Direct-acting oral anticoagulants (DOACs) in cirrhosis and cirrhosis-associated portal vein thrombosis","volume":"39","author":"Weinberg","year":"2019","journal-title":"Semin Liver Dis"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:25:12Z","timestamp":1778840712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125000336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2210740125000336"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102553","relation":{},"ISSN":["2210-7401"],"issn-type":[{"value":"2210-7401","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements of direct oral anticoagulants in cirrhotic individuals with portal vein thrombosis","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102553","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102553"}}